Cargando…
Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study
This study aimed to assess the prevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) total antibodies in the north, middle, and south regions of West Bank and the prevalence of SARS-CoV-2 specific antibodies (IgA, IgM, and IgG) in the Palestinian population. This was a cross-sec...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500452/ https://www.ncbi.nlm.nih.gov/pubmed/34624024 http://dx.doi.org/10.1371/journal.pone.0258255 |
_version_ | 1784580451685367808 |
---|---|
author | Maraqa, Beesan Basha, Walid Khayyat, Rasha Abdul-Hadi, Abdul-Rahman Jabareen, Jurouh Al-Shakhra, Kamal Al-Kaila, Mai Nazzal, Zaher |
author_facet | Maraqa, Beesan Basha, Walid Khayyat, Rasha Abdul-Hadi, Abdul-Rahman Jabareen, Jurouh Al-Shakhra, Kamal Al-Kaila, Mai Nazzal, Zaher |
author_sort | Maraqa, Beesan |
collection | PubMed |
description | This study aimed to assess the prevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) total antibodies in the north, middle, and south regions of West Bank and the prevalence of SARS-CoV-2 specific antibodies (IgA, IgM, and IgG) in the Palestinian population. This was a cross-sectional study. The serological and epidemiological data of 1269 persons were assessed. Participants were selected randomly among primary health care center attendees in Palestine between November 1, 2020 and December 31, 2020. All serum samples were tested for total antibodies using an enzyme-linked immunosorbent assay (ELISA) test. IgM, IgG, and IgA-specific antibody titers were measured using ELISA. The overall prevalence (with 95% confidence intervals [CIs]) of SARS-CoV-2 total antibodies and specific antibodies were estimated. A multivariate regression model was used to assess the predictive factors for SARS-CoV-2-specific antibodies. The overall seroprevalence of SARS-CoV-2 antibodies was 24·0% (95% CI, 21·7%–26·5%). Seroprevalence was significantly higher among people living in south West Bank (adjusted Odds ratio [aOR], 2·22; 95% CI: 1·58–3·11), people who had COVID-19 symptoms (aOR, 3·92; 95% CI, 2·83–5·43), people with a COVID-19 contact history (aOR, 1·44; 95% CI, 1·03–2·03), patients with hypertension (aOR, 1·57; 95% CI, 1·06–2·33), and non-smokers (aOR, 0·47; 95% CI, 0·31–0·72). A total of 171 blood samples from SARS-CoV-2-positive patients were chosen at random for additional serological testing. Specific IgM, IgG, and IgA antibodies were positive in 14·0% (95% CI, 9·2%–20·2%), 88·3% (82·5%–92·7%), and 42·1% (34·6%–59·9%) of the samples, respectively. SARS-CoV-2 antibodies were common among PHC center attendees and were significantly associated to sex, smoking, and COVID-19 contact history. However, considering that almost three-quarters of this population remains susceptible, maintaining public health measures and encouraging access to immunization is critical in protecting this population. |
format | Online Article Text |
id | pubmed-8500452 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-85004522021-10-09 Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study Maraqa, Beesan Basha, Walid Khayyat, Rasha Abdul-Hadi, Abdul-Rahman Jabareen, Jurouh Al-Shakhra, Kamal Al-Kaila, Mai Nazzal, Zaher PLoS One Research Article This study aimed to assess the prevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) total antibodies in the north, middle, and south regions of West Bank and the prevalence of SARS-CoV-2 specific antibodies (IgA, IgM, and IgG) in the Palestinian population. This was a cross-sectional study. The serological and epidemiological data of 1269 persons were assessed. Participants were selected randomly among primary health care center attendees in Palestine between November 1, 2020 and December 31, 2020. All serum samples were tested for total antibodies using an enzyme-linked immunosorbent assay (ELISA) test. IgM, IgG, and IgA-specific antibody titers were measured using ELISA. The overall prevalence (with 95% confidence intervals [CIs]) of SARS-CoV-2 total antibodies and specific antibodies were estimated. A multivariate regression model was used to assess the predictive factors for SARS-CoV-2-specific antibodies. The overall seroprevalence of SARS-CoV-2 antibodies was 24·0% (95% CI, 21·7%–26·5%). Seroprevalence was significantly higher among people living in south West Bank (adjusted Odds ratio [aOR], 2·22; 95% CI: 1·58–3·11), people who had COVID-19 symptoms (aOR, 3·92; 95% CI, 2·83–5·43), people with a COVID-19 contact history (aOR, 1·44; 95% CI, 1·03–2·03), patients with hypertension (aOR, 1·57; 95% CI, 1·06–2·33), and non-smokers (aOR, 0·47; 95% CI, 0·31–0·72). A total of 171 blood samples from SARS-CoV-2-positive patients were chosen at random for additional serological testing. Specific IgM, IgG, and IgA antibodies were positive in 14·0% (95% CI, 9·2%–20·2%), 88·3% (82·5%–92·7%), and 42·1% (34·6%–59·9%) of the samples, respectively. SARS-CoV-2 antibodies were common among PHC center attendees and were significantly associated to sex, smoking, and COVID-19 contact history. However, considering that almost three-quarters of this population remains susceptible, maintaining public health measures and encouraging access to immunization is critical in protecting this population. Public Library of Science 2021-10-08 /pmc/articles/PMC8500452/ /pubmed/34624024 http://dx.doi.org/10.1371/journal.pone.0258255 Text en © 2021 Maraqa et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Maraqa, Beesan Basha, Walid Khayyat, Rasha Abdul-Hadi, Abdul-Rahman Jabareen, Jurouh Al-Shakhra, Kamal Al-Kaila, Mai Nazzal, Zaher Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study |
title | Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study |
title_full | Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study |
title_fullStr | Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study |
title_full_unstemmed | Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study |
title_short | Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study |
title_sort | prevalence of sars-cov-2 antibodies in the palestinian population: a primary health center-based cross-sectional study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500452/ https://www.ncbi.nlm.nih.gov/pubmed/34624024 http://dx.doi.org/10.1371/journal.pone.0258255 |
work_keys_str_mv | AT maraqabeesan prevalenceofsarscov2antibodiesinthepalestinianpopulationaprimaryhealthcenterbasedcrosssectionalstudy AT bashawalid prevalenceofsarscov2antibodiesinthepalestinianpopulationaprimaryhealthcenterbasedcrosssectionalstudy AT khayyatrasha prevalenceofsarscov2antibodiesinthepalestinianpopulationaprimaryhealthcenterbasedcrosssectionalstudy AT abdulhadiabdulrahman prevalenceofsarscov2antibodiesinthepalestinianpopulationaprimaryhealthcenterbasedcrosssectionalstudy AT jabareenjurouh prevalenceofsarscov2antibodiesinthepalestinianpopulationaprimaryhealthcenterbasedcrosssectionalstudy AT alshakhrakamal prevalenceofsarscov2antibodiesinthepalestinianpopulationaprimaryhealthcenterbasedcrosssectionalstudy AT alkailamai prevalenceofsarscov2antibodiesinthepalestinianpopulationaprimaryhealthcenterbasedcrosssectionalstudy AT nazzalzaher prevalenceofsarscov2antibodiesinthepalestinianpopulationaprimaryhealthcenterbasedcrosssectionalstudy |